دورية أكاديمية
أعرض في EDS

Analysis of adverse drug events as a way to improve cancer patient care.

التفاصيل البيبلوغرافية
العنوان: Analysis of adverse drug events as a way to improve cancer patient care.
المؤلفون: Vicente-Oliveros N; Pharmacy, Ramon y Cajal University Hospital. IRYCIS, Madrid, Spain noelia.vicente@salud.madrid.org., Gramage-Caro T; Pharmacy, Ramon y Cajal University Hospital. IRYCIS, Madrid, Spain., Corral de la Fuente E; Early Phase Clinical Drug Development in Oncology, South Texas Accelerated Research Therapeutics (START). Centro Integral Oncológico Clara Campal (CIOCC), Madrid, Spain., Delgado-Silveira E; Pharmacy, Ramon y Cajal University Hospital. IRYCIS, Madrid, Spain., Álvarez-Díaz AM; Pharmacy, Ramon y Cajal University Hospital. IRYCIS, Madrid, Spain.
المصدر: European journal of hospital pharmacy : science and practice [Eur J Hosp Pharm] 2023 Dec 27; Vol. 31 (1), pp. 27-30. Date of Electronic Publication: 2023 Dec 27.
نوع المنشور: Journal Article; Observational Study
اللغة: English
بيانات الدورية: Publisher: BMJ Publishing Group Country of Publication: England NLM ID: 101578294 Publication Model: Electronic Cited Medium: Print ISSN: 2047-9956 (Print) Linking ISSN: 20479956 NLM ISO Abbreviation: Eur J Hosp Pharm Subsets: MEDLINE
أسماء مطبوعة: Original Publication: London : BMJ Publishing Group
مواضيع طبية MeSH: Drug-Related Side Effects and Adverse Reactions*/diagnosis , Drug-Related Side Effects and Adverse Reactions*/epidemiology , Drug-Related Side Effects and Adverse Reactions*/prevention & control , Neoplasms*/diagnosis , Neoplasms*/drug therapy , Neoplasms*/epidemiology, Humans ; Artificial Intelligence ; Patient Care ; Quality of Life
مستخلص: Purpose: To define the signals that a new artificial intelligence (AI) system must emit to improve adverse drug events (ADEs) management in oral antineoplastic agents (OAA).
Methods: A multidisciplinary group of experts in patient safety was set up to define what signals the new AI system must emit to improve ADEs management in OAAs. The baseline data for the new AI system were generated through an observational and ambispective study carried out in a university hospital. All patients who met the inclusion criteria were selected consecutively every working day for 6 months. The ADEs were collected by interview and by the review of health records. The ADEs were categorised according to how they could be detected: patient, analysis, examination.
Results: The group defined what signals the AI system must emit to improve ADEs management in OAAs: a signal to educate the patient when the possible ADEs were categorised as patient, a signal as a reminder to request a blood test or a microbiological culture when the possible ADEs were categorised as analysis, and a signal as a reminder for the necessity of a clinical examination when the possible ADEs were categorised as examination. A total of 1652 ADEs were reported in the interviews (ADE-interview) with the pharmacist, and doctors noted 1989 ADEs in the health record (ADE-HR). The most frequent ADEs were identified in the patient category.
Conclusion: This study opens a new way for better management of ADEs and is the first step in the development of a future technology, which will improve the quality of life of patients.
Competing Interests: Competing interests: None declared.
(© European Association of Hospital Pharmacists 2024. No commercial re-use. See rights and permissions. Published by BMJ.)
References: Drug Saf. 2017 May;40(5):419-430. (PMID: 28205099)
Arch Intern Med. 2005 Jan 24;165(2):234-40. (PMID: 15668373)
Biochem Med (Zagreb). 2012;22(3):276-82. (PMID: 23092060)
Res Social Adm Pharm. 2009 Sep;5(3):225-33. (PMID: 19733823)
Pharmacy (Basel). 2018 Mar 08;6(1):. (PMID: 29518017)
Am J Health Syst Pharm. 2020 Sep 18;77(19):1556-1570. (PMID: 32620944)
Top Geriatr Rehabil. 2019 Jan-Mar;35(1):15-30. (PMID: 31011239)
J Oncol Pharm Pract. 2019 Mar;25(2):449-453. (PMID: 28841100)
J Biomed Inform. 2007 Dec;40(6 Suppl):S40-5. (PMID: 17950041)
Psychol Bull. 1968 Oct;70(4):213-20. (PMID: 19673146)
Br J Clin Pharmacol. 2018 Jul;84(7):1514-1524. (PMID: 29522255)
Expert Opin Drug Saf. 2016;15(4):427-35. (PMID: 26854363)
Br J Clin Pharmacol. 2017 Feb;83(2):227-246. (PMID: 27558545)
J BUON. 2015 May-Jun;20(3):690-8. (PMID: 26214619)
Eur J Clin Pharmacol. 2013 Dec;69(12):2083-94. (PMID: 23893047)
BMJ. 2004 Sep 4;329(7465):573. (PMID: 15345644)
Br J Clin Pharmacol. 2009 May;67(5):558-64. (PMID: 19552751)
Am J Med. 2009 Feb;122(2):114-20. (PMID: 19185083)
BMJ. 2015 Feb 26;350:h796. (PMID: 25722024)
Am J Med. 2018 Feb;131(2):129-133. (PMID: 29126825)
Health Policy. 2017 Mar;121(3):257-264. (PMID: 28073580)
JAMA. 1998 Apr 15;279(15):1200-5. (PMID: 9555760)
فهرسة مساهمة: Keywords: Antineoplastic agents; BIOTECHNOLOGY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; Quality of Health Care; Safety
تواريخ الأحداث: Date Created: 20220325 Date Completed: 20231229 Latest Revision: 20240124
رمز التحديث: 20240124
مُعرف محوري في PubMed: PMC10800239
DOI: 10.1136/ejhpharm-2021-003199
PMID: 35332064
قاعدة البيانات: MEDLINE
الوصف
تدمد:2047-9956
DOI:10.1136/ejhpharm-2021-003199